Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24917151 | 0.80 | RAB9A (0.34) | — | |
| SCHEMBL15741229 | 0.75 | RAB9A (0.35) | JAK2 | |
| SCHEMBL26065245 | 0.75 | NPC1 (0.32) | — | |
| SCHEMBL22528571 | 0.74 | JAK2 (0.33) | CHRNA7JAK2ROCK2PRKCAPRKCQ | |
| SCHEMBL17119432 | 0.72 | KDM4E (0.41) | — | |
| SCHEMBL2674889 | 0.72 | JAK2 (0.43) | CHRNA7MBOAT4JAK2ROCK2PRKCA | |
| SCHEMBL19121885 | 0.72 | RAB9A (0.31) | — | |
| SCHEMBL30595914 | 0.72 | JAK2 (0.43) | CHRNA7MBOAT4JAK2ROCK2PRKCA | |
| SCHEMBL24620353 | 0.71 | JAK2 (0.44) | CHRNA7MBOAT4JAK2ROCK2PRKCA | |
| SCHEMBL1478668 | 0.69 | JAK2 (0.43) | MBOAT4JAK2ROCK2PRKCAPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109906224-B | Triazolopyridine compounds and uses thereof | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | EZH2, EED, BMI1 | CHRNA7 1308/4885MBOAT4 4683/4885JAK2 25/4885 |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | EZH2, EED, BMI1 | CHRNA7 1308/4885MBOAT4 4683/4885JAK2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.